Enhanced efficacy of selumetinib by pretreatment of 5-FU in preclinical Ras/Raf-mutant colorectal cancer models

被引：0
|
作者：
Jang, Hye Yeon
Lee, Haeng Jung
Nam, Yeo Jin
Kim, Won Dong
Bae, Yong Ju
Jung, Jin Hwang
Lee, Seung Jin
Moon, Dae Hyuk
机构：
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.AM2017-1204
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1204
引用
收藏
页数：2
相关论文
共 50 条
  • [21] MYC as a candidate upstream controller involved in TYMS gene expression and 5-FU/folate treatment efficacy in colorectal cancer.
    Drubin, David A.
    Hess, Anne-Katrin
    Catlett, Natalie L.
    Di Cara, Alessandro
    Wettergren, Yvonne
    Tell, Roger
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [22] K-ras Mutation is a Negative Prognostic Marker, and Does Not Preclude Benefit From 5-FU in Stage II/III Colorectal Cancer
    Southward, K.
    Hutchins, G.
    Handley, K.
    Magill, L.
    Beaumont, C.
    Stalhschmidt, J.
    Richman, S.
    Chambers, P.
    Seymour, M.
    Kerr, D.
    Gray, R.
    Quirke, P.
    JOURNAL OF PATHOLOGY, 2011, 224 : S4 - S4
  • [23] Vinorelbine, cyclophosphamide and 5-FU effects on the circulating and intratumoural landscape of immune cells improve anti-PD-L1 efficacy in preclinical models of breast cancer and lymphoma
    Orecchioni, Stefania
    Talarico, Giovanna
    Labanca, Valentina
    Calleri, Angelica
    Mancuso, Patrizia
    Bertolini, Francesco
    BRITISH JOURNAL OF CANCER, 2018, 118 (10) : 1329 - 1336
  • [24] Vinorelbine, cyclophosphamide and 5-FU effects on the circulating and intratumoural landscape of immune cells improve anti-PD-L1 efficacy in preclinical models of breast cancer and lymphoma
    Stefania Orecchioni
    Giovanna Talarico
    Valentina Labanca
    Angelica Calleri
    Patrizia Mancuso
    Francesco Bertolini
    British Journal of Cancer, 2018, 118 : 1329 - 1336
  • [25] Vinorelbine, cyclophosphamide, and 5-FU effects on the circulating and intratumoral landscape of immune cells improve anti-PD-L1 efficacy in preclinical models of breast cancer and lymphoma
    Orecchioni, Stefania
    Talarico, Giovanna
    Labanca, Valentina
    Mancuso, Patrizia
    Bertolini, Francesco
    CANCER RESEARCH, 2018, 78 (13)
  • [26] Synergistic combination of PMBA and 5-fluorouracil (5-FU) in targeting mutant KRAS in 2D and 3D colorectal cancer cells
    Qayum, Arem
    Magotra, Asmita
    Shah, Syed Mohmad
    Nandi, Utpal
    Sharma, P. R.
    Shah, Bhahwal Ali
    Singh, Shashank Kumar
    HELIYON, 2022, 8 (04)
  • [27] Efficacy of 5-FU/LV plus CPT-11 as first-line adjuvant chemotherapy for stage IIIa colorectal cancer
    Mukai, Masaya
    Okada, Kazutake
    Fukumitsu, Hiroshi
    Yazawa, Naoki
    Hoshikawa, Tatsuhiko
    Tajima, Takayuki
    Hirakawa, Hitoshi
    Ogoshi, Kyouji
    Makuuchi, Hiroyasu
    ONCOLOGY REPORTS, 2009, 22 (03) : 621 - 629
  • [28] EFFICACY OF CAPECITABINE VS. 5-FU IN COLORECTAL AND GASTRIC CANCER: UPDATED META-ANALYSIS OF SURVIVAL IN 6 CLINICAL TRIALS
    Cassidy, J.
    Saltz, L.
    Twelves, C.
    Van Cutsem, E.
    Hoff, P.
    Kang, Y.
    Saini, J.
    Gilberg, F.
    Cunningham, D.
    ANNALS OF ONCOLOGY, 2010, 21 : 79 - 79
  • [29] Comparison of efficacy and safety of capecitabine (CAP) compared with intravenous continuous infusion (CIV) of 5-FU administration in advanced colorectal cancer (CRC).
    Cole, S
    Carey, D
    Saif, MW
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 268S - 268S
  • [30] Efficacy and safety of bevacizumab in combination with irinotecan and infusional 5-FU as first-line treatment for patients with metastatic colorectal cancer.
    Sobrero, A.
    Ackland, S.
    Carrion, R. P.
    Chiara, S.
    Clarke, S.
    Giron, C. G.
    Langer, B.
    Zurlo, A.
    Young, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 157S - 157S
12345